Dogwood Therapeutics, Inc (NASDAQ:DWTX) Shares Shorted: Short Interest Up 60.4% in October

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 62,406 shares, an increase of 60.4% from the September 30th total of 38,895 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 76,074 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DWTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Thursday, October 22nd. HC Wainwright restated a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Trading Down 9.4%

Shares of DWTX stock opened at $1.10 on Tuesday. The company’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.98. Dogwood Therapeutics has a 52 week low of $1.07 and a 52 week high of $7.04. The company has a market cap of $37.56 million, a PE ratio of -0.12 and a beta of 1.92.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). Equities research analysts expect that Dogwood Therapeutics will post -0.80 EPS for the current fiscal year.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.